U.S. Biotech firm, Moderna has announced that its trial vaccine for teens has proven to be 100 percent effective.
The pharmaceutical firm has announced their vaccine is fully effective in children aged between 12 to 17 years.
Following this new milestone, the pharmaceutical giant will be seeking to submit data and get approval from the food and drug agency from June.
In a study, known as the Teencove study, Moderna enrolled more than 3,700 participants ages 12 to less than 18 years in the U.S.
Moderna says no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.
Speaking on the study, Moderna CEO, Stephane Bancel said the pharmaceutical firm plans to submit the data to regulators globally in early June.
According to Moderna, the most common solicited local adverse event was injection site pain while the most common solicited systemic adverse events after the second dose were headache, fatigue, myalgia, and chills.
All participants will be monitored for 12 months after their second injection to assess long-term protection and safety.
Moderna now becomes the third vaccine manufacturer to seek approval and if successful, vaccinate children.
Pfizer and Biotech requested expanded use of their shot in adolescents on April 9 of 2021 and were authorized by the FDA on May 10, 2021.
